Fig. 7.

Combination ALT-803 therapy with cetuximab reduces SCCHN tumor burden in nude mice. Nude mice were injected with 3 × 10⁶ CAL27 cells and treatment was started once tumors were palpable. Mice were treated i.p. every 3 days with PBS control, cetuximab (0.25 mg/kg), ALT-803 (5 mg/kg), or the combination of ALT-803 and cetuximab. Mice were monitored for tumor growth over the course of treatment. n = 5 mice per group, bars = SE; *P < 0.001 compared to control; †P < 0.01 compared to ALT-803-alone group; ^#P < 0.01 combination ALT-803 and cetuximab compared to cetuximab-alone group